Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Exocel Bio is a private U.S.-based biotechnology company focused on exosome-enabled regenerative aesthetics and professional skincare. The company develops and commercializes exosome products for skin and hair rejuvenation, centered on its Exovex line for use by aesthetic professionals after procedures such as microneedling and energy-based treatments. Its platform is based on extracellular vesicle technology and mesenchymal stem cell-derived exosomes, with in-house emphasis on quality control, cGMP manufacturing, and cleanroom production. In addition to commercial aesthetic products, Exocel Bio also markets laboratory services related to exosome isolation, nanoparticle analysis, and growth factor production. The company appears to operate primarily in the professional aesthetics segment rather than as a traditional therapeutics developer with a disclosed clinical drug pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Exocel Bio.